Jump to main content

Knopp Biosciences

Knopp Biosciences

Overview

  • Clinical Programs: Immunology and Hematology

    Knopp is advancing dexpramipexole as an anti-inflammatory therapeutic based on extensive preclinical and clinical evidence of its activity in modulating white blood cells known as eosinophils.

  • KCNQ2 Preclinical Program

    Knopp is advancing novel agents to activate a key ion channel in nerve cells, targeting a devastating genetic mutation associated with neonatal encephalopathy, as well as epilepsy and neuropathic pain.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.